Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Pearce IP BioBlast™: w/e 05 Jun 2020

by , | Jun 9, 2020

Significant biosimilar activities this week include

29 May 20 | In a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 March 2025.

31 May 20 | Henlius Biotech announced it has received a positive CHMP opinion, recommending marketing authorisation for HLX02 (proposed trastuzumab biosimilar).

01 Jun 20 | Revance Therapeutics and Mylan announced they would move forward with their development of a Botox® biosimilar. Revance and Mylan first signed a collaboration and license agreement for the development of a Botox biosimilar in February 2018.

03 Jun 20 | LiveMint reported that Aurobindo Pharma announced it would sell its biosimilars business to its wholly owned subsidiary, CuraTeQ Biologics in 2019/20 Q4 earnings call.

04 Jun 20 | Mylan and Lupin announced EMA marketing authorisation for Nepexto® (etanercept) for all indications of the reference product Enbrel®.

04 Jun 20 | Bloomberg Law reported on the ongoing US Court of Appeals for the Federal Circuit dispute between Genentech and Amgen regarding bevacizumab. In a hearing on 3 June 2020, Genentech asked the Court to prevent Amgen selling its biosimilar bevacizumab Mvasi® to new patients, despite the trial Court refusing to prevent Amgen’s launch, and the US Court of Appeals refusing to injunct Amgen early in the appeal.  Decision reserved.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News